Global PCOS Diagnostic Market by Product Type (Diagnostic Devices, Diagnostic Kits), by End-Use Industry (Hospitals, Diagnostic Laboratories, Home Care Settings), by Application (Blood Tests, Ultrasound Imaging, Hormonal Assay): Insights & Forecast (2024 – 2030)

As per Intent Market Research, the PCOS Diagnostic Market was valued at USD 3.0 Billion in 2024-e and will surpass USD 5.6 Billion by 2030; growing at a CAGR of 11.0% during 2025 - 2030.

The PCOS (Polycystic Ovary Syndrome) Diagnostic Market is gaining traction due to the increasing prevalence of PCOS globally and the rising awareness surrounding its symptoms and effects on women’s health. PCOS is one of the most common hormonal disorders affecting women of reproductive age, and it can lead to a range of health issues, including infertility, irregular menstruation, and metabolic concerns. As women become more aware of the condition, the demand for early and accurate diagnosis is rising. This is driving the adoption of advanced diagnostic devices and kits in hospitals, diagnostic laboratories, and home care settings, enabling timely detection and management of the syndrome. The market is poised for significant growth, spurred by technological advancements in diagnostic tools and the increasing focus on women’s health and fertility issues.

Diagnostic Devices Are Largest Owing to Precision and Advanced Technology

Diagnostic devices are the largest segment in the PCOS diagnostic market due to their ability to provide high-precision results and assist healthcare professionals in delivering accurate diagnoses. These devices, such as ultrasound machines and hormonal analyzers, are essential for identifying key indicators of PCOS, such as ovarian cysts, hormonal imbalances, and irregular menstrual cycles. Ultrasound imaging is commonly used to detect ovarian cysts, while diagnostic devices that measure hormone levels help assess the presence of hormonal imbalances characteristic of PCOS.

The demand for diagnostic devices continues to grow as healthcare providers seek more reliable and efficient tools for diagnosing PCOS in women. These devices not only enhance the accuracy of diagnosis but also support healthcare professionals in monitoring the progression of the disorder and tailoring treatment plans accordingly. As technology continues to advance, diagnostic devices are expected to remain the dominant choice in the PCOS diagnostic market.

Blood Tests Are Fastest Growing Application Owing to Ease of Use and Accuracy

Blood tests are the fastest-growing application in the PCOS diagnostic market, driven by their ability to provide detailed and accurate measurements of hormone levels associated with PCOS. Hormonal assays, which are typically performed through blood tests, are crucial in diagnosing PCOS as they help detect elevated levels of androgens (male hormones) and imbalances in other hormones such as LH (luteinizing hormone) and FSH (follicle-stimulating hormone). Blood tests offer a non-invasive, straightforward method for assessing hormonal irregularities, which is key to an effective diagnosis.

With the increasing focus on non-invasive diagnostic methods and the growing preference for at-home testing options, blood tests are emerging as a faster, more accessible way to diagnose PCOS. Their accuracy and ease of use make them an attractive option for both healthcare providers and patients, contributing to their rapid growth in the market.

Hospitals End-Use Industry Is Largest Owing to High Patient Volume and Advanced Diagnostic Facilities

Hospitals are the largest end-use industry in the PCOS diagnostic market, driven by the high volume of patients seeking diagnostic services for PCOS symptoms. Hospitals are equipped with advanced diagnostic tools such as ultrasound machines, hormonal analyzers, and blood testing laboratories, which are essential for comprehensive PCOS diagnosis and monitoring. Given the complexity of diagnosing PCOS, hospitals play a crucial role in providing accurate and timely diagnostic services to patients.

The growing number of patients with symptoms related to PCOS, combined with the increasing focus on women’s health, makes hospitals the largest market for diagnostic devices and kits. The ability of hospitals to offer a range of diagnostic services, including both imaging and blood tests, contributes to their dominance in the market.

North America Is Largest Region Owing to High Healthcare Expenditure and Awareness

North America holds the largest share in the PCOS diagnostic market, driven by the high healthcare expenditure, advanced medical infrastructure, and increasing awareness about women’s health. The region's well-established healthcare system, coupled with the growing number of women diagnosed with PCOS, supports the demand for advanced diagnostic devices and kits. Moreover, the rising awareness about PCOS and its symptoms in North America has led to higher demand for early diagnostic methods.

The increasing prevalence of PCOS in North America, combined with the region's emphasis on preventive healthcare and fertility treatments, makes it the largest market for PCOS diagnostics. As more women seek professional care and early diagnosis, the demand for diagnostic tools in this region is expected to remain robust.

Competitive Landscape and Key Players

The PCOS diagnostic market is highly competitive, with key players such as Siemens Healthineers, Abbott Laboratories, GE Healthcare, and Roche Diagnostics leading the industry. These companies offer a wide range of diagnostic devices and kits that cater to the needs of healthcare providers and patients alike. Leading companies focus on the development of innovative, high-precision diagnostic tools, including advanced ultrasound machines, hormonal assay kits, and blood test platforms, to meet the growing demand for accurate PCOS diagnosis.

The competitive landscape is marked by continuous innovation, with companies investing heavily in research and development to enhance the functionality and usability of their diagnostic products. Strategic partnerships, acquisitions, and product launches are common in this market as companies seek to strengthen their market presence and expand their product portfolios. With the growing demand for accurate and accessible diagnostics, the market is expected to remain dynamic, with players focusing on providing solutions that cater to both clinical and at-home diagnostic needs .

List of Leading Companies:

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Ortho Clinical Diagnostics
• Danaher Corporation
• Qiagen
• PerkinElmer
• LabCorp
• Quest Diagnostics
• GE Healthcare
• Fujifilm Medical Systems
• Becton, Dickinson and Company
• Hologic

Recent Developments:

• Roche Diagnostics launched a new hormonal assay test designed to improve the accuracy of PCOS diagnosis.
• Abbott Laboratories announced the release of an advanced diagnostic kit for home use, designed for early PCOS screening.
• Siemens Healthineers expanded its portfolio by introducing a new ultrasound imaging system that enhances the detection of ovarian cysts related to PCOS.
• Thermo Fisher Scientific acquired a leading PCOS diagnostic company to strengthen its position in the hormonal assay segment.
• Bio-Rad Laboratories introduced a next-generation diagnostic device that improves the speed and reliability of PCOS diagnosis

Report Scope: